Long-term treatment of systemic lupus erythematosus with cyclosporin A

Arthritis and Rheumatism

Volumn 40, Issue 1, 1997, Pages 27-35

  Caccavo, Domenico ^a   Laganà, Bruno ^a   Mitterhofer, Anna P ^a   Ferri, Giovanni M ^a   Afeltra, Antonella ^a   Amoroso, Antonio ^a   Bonomo, Lorenzo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Department of Medicina Ciinica ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HUMAN; HYPERTENSION; HYPERTRICHOSIS; LONG TERM CARE; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; TREMOR;

ADOLESCENT; ADULT; BLOOD PLATELETS; CREATININE; CYCLOSPORINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC TESTS; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 0031020977     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400106     Document Type: Article

References (21)

1. Krone M, Leonard WJ, Depper JM, Arya SK, Wong-Staal F, Gallo RC, Waldman TA, Green WC: Cyclosporin A inhibits T cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A 81:5214-5218, 1984
2. Reem GH, Cook LA, Vilcek J: Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. Science 221:63-65, 1983
3. Palacios R: Cyclosporin A inhibits antigen- and lectin-induced but not constitutive production of interleukin 3. Eur J Immunol 15:204-206, 1985
4. Schindler R: Cyclosporin in Autoimmune Diseases. Berlin, Springer Verlag, 1985
5. Bonomo L: Cyclosporin in Autoimmune Disease. Rome, II Pensiero Scientifico Editore, 1990
6. Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ: Cyclosporin in the treatment of lupus nephritis. Am J Nephrol 9:57-60, 1989
7. Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, Bach JF: Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318:663-670, 1988
8. Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, Paulus HE: Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36:75-83, 1993
9. Førre Ø, and the Norwegian Arthritis Study Group: Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 37:1506-1512, 1994
10. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 333:137-141, 1995
11. Bonomo L, Laganà B, Caccavo D, Giorgi A: Cyclosporin in connective tissue autoimmune diseases, The Second Congress on Immunointervention in Autoimmune Diseases: The Role of Sandimmun (Cyclosporin). Paris, May 13-16, 1991
12. Casato M, Bonomo L, Caccavo D, Giorgi A: Clinical effects of cyclosporin in dermatomyositis. Clin Exp Dermatol 15:1212-1213, 1990
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277, 1982
14. Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107-1118, 1989
15. Miescher PA, Miescher A: Combined cyclosporin-steroid treatment of systemic lupus erythematosus. In, Cyclosporin in Autoimmune Disease. Edited by R Schneider. Berlin, Springer-Verlag, 1985
16. Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, Takahara J: Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 37:551-558, 1994
17. Feutren G, Querin S, Noel LH, Chatenoud L, Beaurain G, Tron F, Lesavre P, Bach JF: Effects of cyclosporin in severe systemic lupus erythematosus. J Pediatr 111:1063-1068, 1987
18. Israel-Biet DI, Noel LH, Bach MA: Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin-A treated (NZB × NZW) F1 mice. Clin Exp Immunol 54:359-365, 1983
19. Blank M, Ben-Bassat M, Shoenfeld Y: The effect of cyclosporin A on early and late stages of experimental lupus. Arthritis Rheum 35:1350-1355, 1992
20. Mountz JD, Smith HR, Wilder RL. Patton Reeves J, Steinberg AD: CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J Immunol 138:157-163, 1987
21. Landewé RBM, Goei Thè HS, van Rijthoven AWAM, Breedveld FC, Dijkmans BAC: A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 37:637-643, 1994